Conference abstract
Research articlePublished 2014
Liposomal N-acetylcysteine Modulates the Pathogenesis of P. aeruginosa Isolated from the Lungs of Cystic Fibrosis Patient
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
N-acetylcysteine (NAC) is a mucolytic agent with antimicrobial potential. We evaluated the antimicrobial activity of the free and liposomal NAC (F-NAC; L-NAC) against Pseudomonas aeruginosa. The minimum inhibitory concentrations (MIC), the minimum bactericidal concentrations (MBC) and the in vitro time kill studies of L-NAC were determined by broth-dilution method. Efficacy of the formulations on the production of N-acyl homoserine lactone molecules, virulence factors and motility were determined. Eradication of bacterial community within biofilms was assessed using the Calgary Biofilm Device. The L-NAC Cytotoxicity and anti-bacterial adhesion potential to human lung cells were examined using pulmonary A549 cell lines. The MIC of L-NAC was lower than the free drug (1250 mg/L and 5000 mg/L, respectively). MBC for L-NAC was 2500 mg/L compared to 5000 mg/L for F-NAC. L-NAC at 2500 mg/L killed bacteria in 2 h, whereas F-NAC exhibited the same effect at 5000 mg/L. Quorum sensing was significantly inhibited by L-NAC (P<0.001). At 1/8 MIC, L-NAC reduced the production of bacterial proteases significantly more than that of F-NAC at 1/4 MIC. L-NAC was also able to reduce the bacterial motility at eightfold lower concentration than F-NAC (P<0.001). As for biofilms, L-NAC provided 75% protection against biofilm formation, 90% reduction in the formed biofilms, and a 46% eradication effect on bacterial community within biofilms compared to treated biofilm with PBS (P<0.001). Finally, L-NAC at 2500 mg/L was safe to A549 cells, reduced bacterial adhesion by 15% compared to control (P<0.001). These data indicate that L-NAC formulation is more effective than F-NAC against P. aeruginosa and has the potential to improve therapeutic outcomes in CF patient.
Subjects
NanotechnologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Review article · 28 Feb 2022
Isolates of Pseudomonas Aeruginosa from Cystic Fibrosis Patients
Conference abstract · 30 Jul 2018
Frequency of PmrA, PmrB and mcr-1 genes in pseudomonas aeruginosa isolates from cystic fibrosis patients of mofid children hospital, Tehran, Iran
Research article · 2016
Comparison of Virulence Factors in Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients
Research article · 26 Oct 2014
The Point on N-acetylcysteine in Idiopathic Pulmonary Fibrosis Treatment
More from this journal
The newest in Journal of Nanomedicine & Nanotechnology.
Article · 16 Feb 2026
Evaluation of In vitro Anticancer Activity of Poly Herbal Extract (Vitis vinifera, Nigella sativa and Curcurbita pepo Seeds)
Article · 21 Oct 2025
Green Synthesis of Chromium(III) Oxide Nanoparticles and their Evaluation against Skin Infections
Article · 19 Jun 2025
Potential of Bhasma as Nanomedicine for Disease Management: A Synopsis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nanomedicine & Nanotechnology
- SubjectNanotechnology
- BylineArticles whose byline prints “Ahad Hasanin”
- BylineArticles whose byline prints “Abdelwahab Omri”

